After completing this module, you should be more aware of:

• the prevalence of long COVID and the prevalence of signs and symptoms;
• the wide range in prevalence values and the potential subjectivity of data;
• key symptoms encountered by people experiencing long COVID;
• the NICE/SIGN/RCGP guideline NG188. ‘COVID-19 rapid guideline: managing the long-term effects of COVID-19’;
• definitions around long COVID – acute COVID-19, ongoing symptomatic COVID-19 and post-COVID-19 syndrome;
• the holistic approach to helping people recover from long COVID recommended in NG188;
  when urgent referral is needed;
• the lack of a long-term database preventing specific recommendations on therapies, medicines and other intervention in NG188;
• general principles about self-management for people with long COVID;
• concerns about the lack of specific information and current omissions in NG188, or reference to guidelines on myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CSF);
• similarities in signs and symptoms of long COVID, ME/CSF, SARS, fibromyalgia, chronic Lyme disease and acceptance by the medical profession;
• ME/CSF guidance on medicines and how this may inform the approach to pharmacological interventions in long COVID;
• current theories on the pathophysiology of long COVID.